Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial

Published:September 30, 2022DOI:



      This study evaluated adebrelimab (a programmed death-ligand 1 antibody) plus nab-paclitaxel and carboplatin as perioperative treatment for resectable NSCLC.


      Eligible patients had resectable stage II to III NSCLCs without driver gene. Patients received neoadjuvant treatment with three cycles of intravenous adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (area under the curve 5 mg/mL per min on day 1), of each 21-day cycle before surgical resection, and followed by 16 cycles of adebrelimab (20 mg/kg on day 1 in 3 wk) adjuvant treatment. The primary end point was major pathologic response (MPR) per blinded independent pathologic review.


      A total of 37 patients were enrolled and received planned neoadjuvant therapy. There were 34 patients (91.9%) who underwent surgery. As of data cutoff on January 25, 2022, 19 of the 37 patients (51.4%, 95% confidence interval [CI]: 35.9–66.6) achieved MPR per blinded independent pathologic review and 11 patients (29.7%, 95% CI: 17.5–45.8) achieved pathologic complete response. Furthermore, 26 patients (70.3%, 95% CI: 54.2–82.5) had an objective response per Response Evaluation Criteria in Solid Tumors version 1.1. The 12-month event-free survival rate was 77.8% (95% CI: 54.1–90.3). In addition, 29 patients (78.4%) had grade greater than or equal to three treatment-related adverse events (AEs) and nine (24.3%) had treatment-related serious AEs. No treatment-related deaths occurred. Grade greater than or equal to three surgery-related AEs within 30 or 90 days after surgery were both reported in five patients (14.7%).


      Adebrelimab plus nab-paclitaxel and carboplatin as perioperative therapy led to a substantial proportion of MPR and high resectability, with manageable toxicities. On the basis of the phase 1b results, phase 3 trial was initiated.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Liang Y.
        • Wakelee H.A.
        Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC).
        Transl Lung Cancer Res. 2013; 2: 403-410
        • Taylor M.D.
        • Nagji A.S.
        • Bhamidipati C.M.
        • et al.
        Tumor recurrence after complete resection for non-small cell lung cancer.
        Ann Thorac Surg. 2012; 93: 1813-1821
        • Gu C.D.
        • Osaki T.
        • Oyama T.
        • et al.
        Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival.
        Ann Surg. 2002; 235: 133-139
        • Zheng Y.
        • Jaklitsch M.T.
        • Bueno R.
        Neoadjuvant therapy in non-small cell lung cancer.
        Surg Oncol Clin N Am. 2016; 25: 567-584
        • NSCLC Meta-analysis Collaborative Group
        Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
        Lancet. 2014; 383: 1561-1571
        • Arriagada R.
        • Bergman B.
        • Dunant A.
        • et al.
        Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
        N Engl J Med. 2004; 350: 351-360
        • Pignon J.P.
        • Tribodet H.
        • Scagliotti G.V.
        • et al.
        Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
        J Clin Oncol. 2008; 26: 3552-3559
        • Gandhi L.
        • Rodríguez-Abreu D.
        • Gadgeel S.
        • et al.
        Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.
        N Engl J Med. 2018; 378: 2078-2092
        • Paz-Ares L.
        • Luft A.
        • Vicente D.
        • et al.
        Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.
        N Engl J Med. 2018; 379: 2040-2051
        • Socinski M.A.
        • Jotte R.M.
        • Cappuzzo F.
        • et al.
        Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.
        N Engl J Med. 2018; 378: 2288-2301
        • West H.
        • McCleod M.
        • Hussein M.
        • et al.
        Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2019; 20: 924-937
        • Zhou C.
        • Chen G.
        • Huang Y.
        • et al.
        Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
        Lancet Respir Med. 2021; 9: 305-314
        • Ren S.
        • Chen J.
        • Xu X.
        • et al.
        Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial.
        J Thorac Oncol. 2022; 17: 544-557
        • Felip E.
        • Altorki N.
        • Zhou C.
        • et al.
        Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
        Lancet. 2021; 398: 1344-1357
        • Forde P.M.
        • Spicer J.
        • Lu S.
        • et al.
        Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.
        N Engl J Med. 2022; 386: 1973-1985
        • Mu L.
        • Song Y.
        • Zhao K.
        • et al.
        SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: a multicentre, phase 2 study.
        Thorac Cancer. 2021; 12: 1373-1381
        • Wang J.
        • Zhou C.
        • Yao W.
        • et al.
        Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2022; 23: 739-747
        • Provencio-Pulla M.
        • Nadal E.
        • Larriba J.L.G.
        • et al.
        Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
        J Clin Oncol. 2022; 40: 8501
        • Provencio M.
        • Serna-Blasco R.
        • Nadal E.
        • et al.
        Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial).
        J Clin Oncol. 2022; 40: 2924-2933
        • Provencio M.
        • Nadal E.
        • Insa A.
        • et al.
        Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2020; 21: 1413-1422
        • Shu C.A.
        • Gainor J.F.
        • Awad M.M.
        • et al.
        Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2020; 21: 786-795
        • Hellmann M.D.
        • Chaft J.E.
        • William Jr., W.N.
        • et al.
        Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
        Lancet Oncol. 2014; 15: e42-e50
        • Waser N.A.
        • Adam A.
        • Schweikert B.
        • et al.
        1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): systematic literature review and meta-analysis.
        Ann Oncol. 2020; 31: S806
        • Cortazar P.
        • Zhang L.
        • Untch M.
        • et al.
        Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
        Lancet. 2014; 384: 164-172
        • Mouillet G.
        • Monnet E.
        • Milleron B.
        • et al.
        Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
        J Thorac Oncol. 2012; 7: 841-849
        • Menzies A.M.
        • Amaria R.N.
        • Rozeman E.A.
        • et al.
        Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
        Nat Med. 2021; 27: 301-309
        • Center for Drug Evaluation and Research
        Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval.
        Date accessed: July 5, 2022
        • Qu Y.
        • Emoto K.
        • Eguchi T.
        • et al.
        Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma.
        J Thorac Oncol. 2019; 14: 482-493
        • Wang J.
        • Lu S.
        • Yu X.
        • et al.
        Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial.
        JAMA Oncol. 2021; 7: 709-717
        • Zhou C.
        • Wu L.
        • Fan Y.
        • et al.
        Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
        J Thorac Oncol. 2021; 16: 1501-1511
        • Zhang J.T.
        • Liu S.Y.
        • Gao W.
        • et al.
        Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer.
        Cancer Discov. 2022; 12: 1690-1701